- Price
- $5.41
- Day
- +1.50%
- Mkt Cap
- $1.11B
- 52W Range
- $2.43 – $7.01
- Volume
- 1.30M
- Beta
- 0.24
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Savara Inc. (SVRA) is revisited, focusing on its APAP BLA filing progress. The article assesses SVRA's clinical and regulatory milestones as key investment drivers. Upcoming APAP BLA PDUFA is highlighted as a pivotal near-term catalyst.
Read full article
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has a.
Read full article
SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.
Read full article